The Latest Breaking News from Merck & Co

Someone with a lot of money to spend has taken a bearish stance on Merck & Co (NYSE:MRK). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Someone with a lot of money to spend has taken a bearish stance on Merck & Co (NYSE:MRK). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Someone with a lot of money to spend has taken a bullish stance on Merck & Co (NYSE:MRK). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

  Merck & Co (NYSE:MRK) reported its Q4 earnings results on Thursday, February 3, 2022 at 06:30 AM. Here's what investors need to know about the announcement.

Merck & Co (NYSE:MRK) is set to give its latest quarterly earnings report on Thursday, 2022-02-03. Here's what investors need to know before the announcement. Analysts estimate that Merck & Co will likely report an Earnings Per Share (EPS) of $1.53.

Analysts have provided the following ratings for Merck & Co (NYSE:MRK) within the last quarter:

Egypt approved Merck & Co’s COVID-19 pill Molnupiravir for emergency use, the country’s drug authority said on Monday, adding that the pill would be locally produced. The drug will initially be manufactured by five local companies, to be joined later by several other firms, the Egyptian Drug Authority (EDA) said…